These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 10669335)

  • 1. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
    Günthard HF; Wong JK; Spina CA; Ignacio C; Kwok S; Christopherson C; Hwang J; Haubrich R; Havlir D; Richman DD
    J Infect Dis; 2000 Feb; 181(2):522-31. PubMed ID: 10669335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response.
    Fuller JD; Craven DE; Steger KA; Cox N; Heeren TC; Chernoff D
    Clin Infect Dis; 1999 Mar; 28(3):541-7. PubMed ID: 10194075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
    Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N
    J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy.
    García F; Vidal C; Plana M; Cruceta A; Gallart MT; Pumarola T; Miro JM; Gatell JM
    Clin Infect Dis; 2000 Feb; 30(2):392-4. PubMed ID: 10671348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
    Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
    J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
    Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
    Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
    N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole.
    Feola DJ; Garvy BA; Rapp RP; Thornton AC
    Pharmacotherapy; 2007 Jul; 27(7):937-47. PubMed ID: 17594199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
    Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
    N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
    King JC; Treanor J; Fast PE; Wolff M; Yan L; Iacuzio D; Readmond B; O'Brien D; Mallon K; Highsmith WE; Lambert JS; Belshe RB
    J Infect Dis; 2000 Feb; 181(2):725-8. PubMed ID: 10669363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.